Cargando…

Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus

OBJECTIVE: Cerebrospinal fluid (CSF) shunting can improve symptoms of elderly patients' idiopathic normal pressure hydrocephalus (iNPH). However, adjunctive means for confirming the diagnosis remain unavailable. We have previously reported the specific increase of leucine-rich alpha-2-glycoprot...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Madoka, Miyajima, Masakazu, Ogino, Ikuko, Watanabe, Maki, Miyata, Haruko, Karagiozov, Kostadin L., Arai, Hajime, Hagiwara, Yoshiaki, Segawa, Tatsuya, Kobayashi, Kyoko, Hashimoto, Yasuhiro
Formato: Texto
Lenguaje:English
Publicado: Springer Vienna 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098968/
https://www.ncbi.nlm.nih.gov/pubmed/21336807
http://dx.doi.org/10.1007/s00701-011-0963-z
_version_ 1782204015868641280
author Nakajima, Madoka
Miyajima, Masakazu
Ogino, Ikuko
Watanabe, Maki
Miyata, Haruko
Karagiozov, Kostadin L.
Arai, Hajime
Hagiwara, Yoshiaki
Segawa, Tatsuya
Kobayashi, Kyoko
Hashimoto, Yasuhiro
author_facet Nakajima, Madoka
Miyajima, Masakazu
Ogino, Ikuko
Watanabe, Maki
Miyata, Haruko
Karagiozov, Kostadin L.
Arai, Hajime
Hagiwara, Yoshiaki
Segawa, Tatsuya
Kobayashi, Kyoko
Hashimoto, Yasuhiro
author_sort Nakajima, Madoka
collection PubMed
description OBJECTIVE: Cerebrospinal fluid (CSF) shunting can improve symptoms of elderly patients' idiopathic normal pressure hydrocephalus (iNPH). However, adjunctive means for confirming the diagnosis remain unavailable. We have previously reported the specific increase of leucine-rich alpha-2-glycoprotein (LRG) in iNPH CSF, and the present study investigates its potential clinical applications. METHODS: We performed CSF tap test (TT) on 90 patients (mean age 73.4 years) and shunting in 52 patients (mean age 73.5 years), evaluating symptom improvement and higher cerebral functions—mini-mental state examination (MMSE) and Frontal Assessment Battery (FAB) before and 12 months after shunting. LRG and tau protein concentrations in TT CSF were simultaneously measured using enzyme-linked immunosorbent assay. We then compared the predictive value of these concentrations with TT results regarding successful shunting outcomes. RESULTS: Positive combinations of TT and LRG concentrations of 67 ng/ml or higher, gave 81.6% sensitivity and 78.6% specificity. Therefore we used LRG (67 ng/ml) and tau (200 pg/ml) cut-off values, dividing patients into four groups. In group A (LRG ≥ 67 ng/ml and tau < 200 pg/ml) 31 of 34 patients (91.2%) had a positive TT and all operated 22 patients were shunt responders. Dementia MMSE and FAB scores in them increased from a baseline of 22.05(SE ± 0.96) to 25.65 (±0.85) and 11.38 (±0.68) to 13.08 (±0.57) respectively. In group B, (LRG ≥ 67 ng/ml and tau ≥ 200 pg/ml), the mean MMSE score increased from 17.62 (±2.03) to 21.62 (±1.96), and the FAB decreased slightly from 9.25 (±1.15) to 10.5 (±1.59), without improvement beyond the range of dementia. In group C, (LRG < 67 ng/ml, tau < 200 pg/ml), the mean MMSE score improved from 22.06 (±1.25) to 24.29 (±1.23) and the FAB score improved slightly from 12.0 (±0.72) to 12.87 (±0.72). Finally, in group D, (LRG < 67 ng/ml, tau ≥ 200 pg/ml), there was almost no improvement in MMSE score CONCLUSIONS: A combination of positive TT and biomarkers quantification such as LRG and tau protein, can reliably predict shunting outcome in iNPH patients.
format Text
id pubmed-3098968
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-30989682011-07-14 Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus Nakajima, Madoka Miyajima, Masakazu Ogino, Ikuko Watanabe, Maki Miyata, Haruko Karagiozov, Kostadin L. Arai, Hajime Hagiwara, Yoshiaki Segawa, Tatsuya Kobayashi, Kyoko Hashimoto, Yasuhiro Acta Neurochir (Wien) Clinical Article OBJECTIVE: Cerebrospinal fluid (CSF) shunting can improve symptoms of elderly patients' idiopathic normal pressure hydrocephalus (iNPH). However, adjunctive means for confirming the diagnosis remain unavailable. We have previously reported the specific increase of leucine-rich alpha-2-glycoprotein (LRG) in iNPH CSF, and the present study investigates its potential clinical applications. METHODS: We performed CSF tap test (TT) on 90 patients (mean age 73.4 years) and shunting in 52 patients (mean age 73.5 years), evaluating symptom improvement and higher cerebral functions—mini-mental state examination (MMSE) and Frontal Assessment Battery (FAB) before and 12 months after shunting. LRG and tau protein concentrations in TT CSF were simultaneously measured using enzyme-linked immunosorbent assay. We then compared the predictive value of these concentrations with TT results regarding successful shunting outcomes. RESULTS: Positive combinations of TT and LRG concentrations of 67 ng/ml or higher, gave 81.6% sensitivity and 78.6% specificity. Therefore we used LRG (67 ng/ml) and tau (200 pg/ml) cut-off values, dividing patients into four groups. In group A (LRG ≥ 67 ng/ml and tau < 200 pg/ml) 31 of 34 patients (91.2%) had a positive TT and all operated 22 patients were shunt responders. Dementia MMSE and FAB scores in them increased from a baseline of 22.05(SE ± 0.96) to 25.65 (±0.85) and 11.38 (±0.68) to 13.08 (±0.57) respectively. In group B, (LRG ≥ 67 ng/ml and tau ≥ 200 pg/ml), the mean MMSE score increased from 17.62 (±2.03) to 21.62 (±1.96), and the FAB decreased slightly from 9.25 (±1.15) to 10.5 (±1.59), without improvement beyond the range of dementia. In group C, (LRG < 67 ng/ml, tau < 200 pg/ml), the mean MMSE score improved from 22.06 (±1.25) to 24.29 (±1.23) and the FAB score improved slightly from 12.0 (±0.72) to 12.87 (±0.72). Finally, in group D, (LRG < 67 ng/ml, tau ≥ 200 pg/ml), there was almost no improvement in MMSE score CONCLUSIONS: A combination of positive TT and biomarkers quantification such as LRG and tau protein, can reliably predict shunting outcome in iNPH patients. Springer Vienna 2011-02-19 2011 /pmc/articles/PMC3098968/ /pubmed/21336807 http://dx.doi.org/10.1007/s00701-011-0963-z Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Clinical Article
Nakajima, Madoka
Miyajima, Masakazu
Ogino, Ikuko
Watanabe, Maki
Miyata, Haruko
Karagiozov, Kostadin L.
Arai, Hajime
Hagiwara, Yoshiaki
Segawa, Tatsuya
Kobayashi, Kyoko
Hashimoto, Yasuhiro
Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus
title Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus
title_full Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus
title_fullStr Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus
title_full_unstemmed Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus
title_short Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus
title_sort leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus
topic Clinical Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098968/
https://www.ncbi.nlm.nih.gov/pubmed/21336807
http://dx.doi.org/10.1007/s00701-011-0963-z
work_keys_str_mv AT nakajimamadoka leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT miyajimamasakazu leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT oginoikuko leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT watanabemaki leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT miyataharuko leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT karagiozovkostadinl leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT araihajime leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT hagiwarayoshiaki leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT segawatatsuya leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT kobayashikyoko leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus
AT hashimotoyasuhiro leucinericha2glycoproteinisamarkerforidiopathicnormalpressurehydrocephalus